BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30815926)

  • 21. Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy.
    Halfon P; Benmoura D; Agostini A; Khiri H; Pénaranda G; Martineau A; Blanc B
    Cancer Biomark; 2010; 7(3):133-9. PubMed ID: 21263189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
    Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
    J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing.
    Alonso I; Torné A; Puig-Tintoré LM; Esteve R; Quinto L; Garcia S; Campo E; Pahisa J; Ordi J
    Am J Obstet Gynecol; 2007 Oct; 197(4):359.e1-6. PubMed ID: 17714678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.
    Denise Zielinski G; Snijders PJ; Rozendaal L; Voorhorst FJ; Runsink AP; de Schipper FA; Meijer CJ
    J Pathol; 2001 Oct; 195(3):300-6. PubMed ID: 11673826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.
    Persson M; Brismar Wendel S; Ljungblad L; Johansson B; Weiderpass E; Andersson S
    Oncol Rep; 2012 Jul; 28(1):346-52. PubMed ID: 22484610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A study of cervical cancer screening algorithms].
    Zhao FH; Zhang WH; Pan QJ; Zhang X; Chen W; Liu B; Ma JF; Hu SY; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):420-4. PubMed ID: 20819481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic performance of HPV E6/E7 mRNA assay for detection of cervical high-grade intraepithelial neoplasia and cancer among women with ASCUS Papanicolaou smears.
    Ren C; Zhu Y; Yang L; Zhang X; Liu L; Ren C
    Arch Gynecol Obstet; 2018 Feb; 297(2):425-432. PubMed ID: 29143102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
    Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
    J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions.
    Dockter J; Schroder A; Hill C; Guzenski L; Monsonego J; Giachetti C
    J Clin Virol; 2009 Jul; 45 Suppl 1():S55-61. PubMed ID: 19651370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation.
    Weston G; Dombrowski C; Harvey MJ; Iftner T; Kyrgiou M; Founta C; Adams EJ
    BMJ Open; 2020 Mar; 10(3):e031303. PubMed ID: 32152154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
    Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
    Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
    Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
    Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
    Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
    J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group.
    Lytwyn A; Sellors JW; Mahony JB; Daya D; Chapman W; Ellis N; Roth P; Lorincz AT; Gafni A
    CMAJ; 2000 Sep; 163(6):701-7. PubMed ID: 11022584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity and specificity values of high-risk HPV DNA, p16/ki-67 and HPV mRNA in young women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL).
    Frega A; Pavone M; Sesti F; Leone C; Bianchi P; Cozza G; Colombrino C; Lukic A; Marziani R; De Sanctis L; Delli Carpini G; Caserta D; Ciavattini A
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10672-10677. PubMed ID: 31858534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples.
    Asciutto KC; Ernstson A; Forslund O; Borgfeldt C
    J Clin Virol; 2018 Apr; 101():69-73. PubMed ID: 29433016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of high-risk human papillomavirus testing in the triage of abnormal cervical cytology among Chinese younger women in Shanghai, China.
    Jiang L; Zeng Y; Li J; Wang H; Xia Y; Fang X; Zhang P
    Asian Pac J Cancer Prev; 2011; 12(11):2963-7. PubMed ID: 22393972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3-year-old PreservCyt samples with low-grade squamous intraepithelial lesion.
    Waldstrøm M; Ornskov D
    Arch Pathol Lab Med; 2011 Aug; 135(8):1052-6. PubMed ID: 21809999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.